Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/4498
Title: | Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-alpha 2A and ribavirin therapy in patients with chronic hepatitis C |
Authors: | ARAUJO, Ana Ruth; PERUHYPE-MAGALHAES, Vanessa; COELHO-DOS-REIS, Jordana Grazziela Alves; CHAVES, Laura Patricia Viana; LIMA, Tatiane Amabili de; PIMENTEL, Joao Paulo Diniz; PAULA, Lucia de; ALMEIDA, Carlos Mauricio de; TARRAGO, Andrea Monteiro; TATENO, Adriana; LEVI, Jose Eduardo; TEIXEIRA-CARVALHO, Andrea; MARTINS-FILHO, Olindo de Assis; LIRA, Edson da Fonseca; TORRES, Katia Luz; TALHARI, Sinesio; MALHEIRO, Adriana |
Citation: | IMMUNOLOGY LETTERS, v.154, n.1-2, p.61-69, 2013 |
Abstract: | Several efforts have been made to establish novel biomarkers with relevant predictive values to monitor HCV-infected patients under pegilated Interferon-alpha 2A-(PEG-IFN-alpha 2A)/ribavirin therapy. The aim of this study was to monitor the kinetics of HCV viral load, serum levels of pro-inflammatory/regulatory cytokines and leukocyte activation status before and after PEG-IFN-alpha 2A/ribavirin therapy in 52 volunteers, including 12 chronic HCV patients and 40 controls. The HCV viral load, serum levels of cytokines (IL-8/IL-6/TNF-alpha/IL-12/IFN-gamma/IL-4/IL-10) and the phenotype of peripheral blood leukocytes were evaluated before and after 4, 12 and 24 weeks following the PEG-IFN-alpha 2A/ribavirin therapy. Our results demonstrated that sustained virological response-(SVR) is associated with early decrease in the viral load after 4 weeks of treatment. The presence of a modulated pro-inflammatory profile at baseline favors SVR, whereas a strong inflammatory response at baseline predisposes to therapeutic failure. Furthermore, a time-dependent increase on serum IL-12 levels in patients under treatment is critical to support the SVR, while the early predominance of IL-10 correlates to late virological relapse. On the other hand, a broad but unguided ""cytokine storm"" is observed in the non-responder HCV patients after 12 weeks of treatment. Corroborating these findings, monocyte/lymphocyte activation at baseline is associated with the non-responders to therapy whereas high CDS+ T-cell numbers associate with SVR. All in all, these data suggest that the baseline pattern of serum pro-inflammatory/regulatory cytokines and the immunological activation status of chronic HCV patients undergoing PEG-IFN-alpha 2A/ribavirin therapy are closely related with the therapeutic response. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - IMT Artigos e Materiais de Revistas Científicas - LIM/52 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_TATENO_Dual_role_of_IL_12_in_the_therapeutic_2013.PDF Restricted Access | publishedVersion (English) | 1.22 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.